These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11014098)

  • 1. [Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].
    Gabay C
    Rev Med Suisse Romande; 2000 Jun; 120(6):529-33. PubMed ID: 11014098
    [No Abstract]   [Full Text] [Related]  

  • 2. The many worlds of reducing interleukin-1.
    Dinarello CA
    Arthritis Rheum; 2005 Jul; 52(7):1960-7. PubMed ID: 15986340
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine blocker licensed for relief of rheumatoid arthritis symptoms.
    Am J Health Syst Pharm; 2002 Feb; 59(3):225-6. PubMed ID: 11862629
    [No Abstract]   [Full Text] [Related]  

  • 6. [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases].
    Sohen S
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():673-6. PubMed ID: 15035207
    [No Abstract]   [Full Text] [Related]  

  • 7. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW; White AJ
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra shows promise for treating patients with rheumatoid arthritis.
    McIntosh T; Freeman TR
    J Am Pharm Assoc (Wash); 2002; 42(4):660-2. PubMed ID: 12150367
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.
    Bresnihan B
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I96-8. PubMed ID: 10577983
    [No Abstract]   [Full Text] [Related]  

  • 10. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S; Burmester GR
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anakinra in the treatment of rheumatoid arthritis].
    Loft AG; Tarp U; Thomsen BS
    Ugeskr Laeger; 2003 Sep; 165(39):3720-4. PubMed ID: 14558384
    [No Abstract]   [Full Text] [Related]  

  • 12. Anakinra (Kineret) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2002 Feb; 44(1124):18-9. PubMed ID: 11856953
    [No Abstract]   [Full Text] [Related]  

  • 13. The trials of anakinra.
    Burls A; Jobanputra P
    Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
    [No Abstract]   [Full Text] [Related]  

  • 14. Kineret. Easing the pain of rheumatoid arthritis.
    Nursing; 2002 Apr; 32(4):26. PubMed ID: 11969009
    [No Abstract]   [Full Text] [Related]  

  • 15. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 17. Bringing the clinical experience with anakinra to the patient.
    Cohen SB; Rubbert A
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes.
    Jones NC; Prior MJ; Burden-Teh E; Marsden CA; Morris PG; Murphy S
    Eur J Neurosci; 2005 Jul; 22(1):72-8. PubMed ID: 16029197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations of the Deutschen Gesellschaft für Rheumatologie on therapy of rheumatoid arthritis with the interleukin-1-receptor-antagonist Akakinra (KINERET)].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):698-700. PubMed ID: 12491134
    [No Abstract]   [Full Text] [Related]  

  • 20. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.